Biosafety and selectable markers

Annals of the New York Academy of Sciences

Volumn 1105, Issue , 2007, Pages 405-417

  Titball, Richard W ^a,b   Sjöstedt, Anders ^c   Pavelka Jr , Martin S ^d   Nano, Francis E ^e  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Biosafety; Containment; Francisella tularensis; Genetic manipulation; Laboratory; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; BETA LACTAM; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LIVE VACCINE; STREPTOMYCIN; TETRACYCLINE; BIOLOGICAL MARKER;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; BIOSAFETY; CLINICAL TRIAL; FRANCISELLA TULARENSIS; GENETIC MANIPULATION; GENETICS; HUMAN; IMMUNIZATION; INFECTION; LABORATORY TEST; MEDICAL STAFF; NONHUMAN; PATIENT MONITORING; REVIEW; TRAINING; TULAREMIA; VACCINATION; ANIMAL; ANIMAL EXPERIMENT; METABOLISM; OCCUPATIONAL HEALTH; PATHOGENICITY; PERSONNEL; STANDARD; WORKPLACE; ZOONOSIS;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS;

ANIMAL EXPERIMENTATION; ANIMALS; BACTERIAL VACCINES; BIOLOGICAL MARKERS; FRANCISELLA TULARENSIS; HUMANS; OCCUPATIONAL HEALTH; RESEARCH PERSONNEL; TULAREMIA; WORKPLACE; ZOONOSES;

EID: 34748868496     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1409.002     Document Type: Review

References (33)

1. SJOSTEDT, A. 2003. Gram-negative aerobic cocci. Family XVII. Francisellaceae. In Bergey's Manual of Sytematic Bacteriology. D.J. Brenner, Ed. Springer-Verlag. New York.
2. OLSUFJEV, N. G. & I. S. MESHCHERYAKOVA. 1983. Subspecific taxonomy of Francisella tularensis McCoy and Chapin 1912. Int. J. Syst. Bacteriol. 33: 872-874.
3. DIENST, F. T. 1963. Tularemia a perusal of three hundred thirty-nine cases. J. La. State. Med. Soc. 115: 114-127.
4. STUART, B. M. & R. I. PULLEN. 1945. Tularemic pneumonia: review of American literature and report of 15 additional cases. Am. J. Med. Sci. 210: 223-236.
5. ELLIS, J. et al. 2002. Tularemia Clin. Microbiol. Rev. 15: 631-646.
6. HOLLIS, D. G. et al. 1989. Francisella philomiragia comb. nov. (formerly Yersinia philomiragia) and Francisella tularensis biogroup novicida (formerly Francisella novicida) associated with human disease. J. Clin. Microbiol. 27: 1601-1608.
7. MCCRUMB, F. R. 1961. Aerosol infection of man with Pasteurella tularensis. Bacteriol. Revs. 25: 262-267.
8. FELDMAN, K. A. et al. 2001. An outbreak of primary pneumonic tularemia on Martha's vineyard. N. Engl. J. Med. 345: 1601-1637.
9. HORNICK, R. B. et al. 1966. Oral tularemia vaccine in man. Antimicrob. Agents Chemother. 6: 11-14.
10. SASLAW, S. et al. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107: 702-714.
11. SASLAW, S. et al. 1961. Tularemia vaccine study. I. Intracutaneous Challenge. Arch. Inter. Med. 107: 689-701.
12. HORNICK, R. B. & H. T. EIGELSBACH. 1966. Aerogenic immunization of man with live tularemia vaccine. Bact. Revs. 30: 532-538.
13. OVERHOLT, E. L. et al. 1961. An analysis of forty-two cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics. Am. J. Med. 30: 785-806.
14. RUSNAK, J. M. et al. 2004. Rick of occupationally acquired illness from biological threat agents in unvaccinated laboratory workers. Biosec. Bioterror. Biodef. Strat. Prac. Sci. 2: 1-13.
15. DENNIS, D. T. et al. 2001. Tularemia as a biological weapon - Medical and public health management. JAMA 285: 2763-2773.
16. STEWART, S. J. 1996. Tularemia: association with hunting and farming. FEMS Immunol. Med. Microbiol. 13: 197-199.
17. WAAG, D.M. et al. 1992. Cell mediated and humoral immune responses induced by scarification vaccination of human volunteers with a new lot of the live vaccine strain of Francisella tularensis. J. Clin. Microbiol. 30: 2256-2264.
18. WAAG, D.W. et al. 1995. Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin. Diagn. Lab. Immunol. 2: 143-148.
19. WAAG, D. W. et al. 1996. Immunogenicity of a new lot of Francisella tularensis live vaccine strain in human volunteers. FEMS Immunol. Med. Microbiol. 13: 205-209.
20. EIGELSBACH, H. T., R. B. HORNICK & J. J. TULIS. 1967. Recent studies on live tularemia vaccine. Med. Ann. Dist. Columbia 36: 282-286.
21. BURKE, D. S. 1977. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory acquired tularemia. J. Infect. Dis. 135: 55-60.
22. ANONOMOUS. 2004. Choice of antibacterial drugs. Med. Lett. 2: 13-26.
23. QIN, A. & B. J. MANN. 2006. Identification of transposon insertion mutants of Francisella tularensis strain SchuS4 deficient in intracellular replication. BMC Microbiol. 6: 69.
24. LOVULLO, E. D. et al. 2006. Genetic tools for highly pathogenic Francisella tularensis subsp. tularensis. Microbiol. 152: 3425-3435.
25. MAIER, T. M. et al. 2004. Construction and characterisation of a highly efficient Francisella shuttle plasmid. Appl. Env. Microbiol. 70: 7511-7519.
26. MAIER, T. M. et al. 2006. In vivo Himar1-based transposon mutagenesis of Francisella tularensis. Appl. Env. Microbiol. 72: 1878-1885.
27. KAWULA, T. H. et al. 2004. Use of transposon-transposase complexes to create stable insertion mutant strains of Francisella tularensis LVS. Appl. Env. Microbiol. 70: 6901-6904.
28. SHAW, K. J. et al. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57: 138-163.
29. HAAS, R. et al. 1993. TnMax-a versatile mini-transposon for the analysis of cloned genes and shuttle mutagenesis. Gene 130: 23-31.
30. ANTHONY, L. S. D. et al. 1991. Transformation and allelic replacement in Francisella spp. J. Gen. Microbiol. 137: 2697-2703.
31. GRAY, C. G. et al. 2002. The identification of five genetic loci of Francisella novicida associated with intracellular growth. FEMS Microbiol. Letts. 215: 53-56.
32. NANO, F. E. et al. 2004. A Francisella tularensis pathogenicity island required for intramacrophage growth. J. Bacteriol. 186: 6430-6436.
33. BINA, X. W. R. et al. 2006. The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics. Arch. Microbiol. 186: 219-228.